Formoterol versus montelukast as add on therapy to low dose budesonide in persistent asthma: effect on lung function

Autor:	Anukesh Vasu Keloth, Divya G. Krishnan
Rok vydání:	2018
Předmět:	Budesonide medicine.medical_specialty business.industry Low dose respiratory system Gastroenterology respiratory tract diseases Add on therapy immune system diseases Internal medicine medicine Formoterol Persistent asthma business Montelukast Lung function medicine.drug
Zdroj:	International Journal of Basic & Clinical Pharmacology. 7:1186
ISSN:	2279-0780 2319-2003
Popis:	Background: Choice between LABAs and LTRAs as add on drugs to low dose ICS in persistent asthma remains unclear due to limited data on the comparative efficacy of these two groups of drugs. The aim of this study was to compare the effects of formoterol and montelukast on lung function, when added to low dose Budesonide in persistent asthma.Methods: This was an institution based randomized open label study. 72 asthmatics satisfying selection criteria of the study were randomized to receive either inhaled budesonide and formoterol (FB group) or inhaled budesonide and oral montelukast (MB group) for 12 weeks. PEF value at end point was primary efficacy measure. Secondary efficacy measures were PEF values measured at the end of 1, 4 and 8 weeks and the end point value of FEV1.Results: Both the groups showed significant improvement in the lung function tests. However inter-group comparison showed that PEF value at end point of FB group was significantly greater than that of MB group (81.94%vs 63.82%, p
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::0469661bddf33a07ecadc76996c9b6eb https://doi.org/10.18203/2319-2003.ijbcp20182104 Zobrazit plný text záznamu